Ribo Newsroom
-
Phase II/III study of optic neuroprotective oligonucleotide therapeutics QPI-1007 completed dosing of the first subject in ChinaKunshan RiboQuark Pharmaceutical Technology Co. Ltd. announced that in the global pivotal II/III study QRK207 of its innovative siRNA drug QPI-1007 for optic nerve protection, the investigational product has been administered to the first subject by Professor Wang Ningli's team at Beijing Tongren Hospital, Capital Medical University, China.November 13, 2017 -
Ribo successfully raised 270 million yuan in its Series B financingOn April 21, 2017, Suzhou Ribo Life Science Co., Ltd. announced the successful completion of Series B private equity financing of RMB 270 million (about $40 million), which introduced strong capital support for developing China's oligonucleotide pharmaceutical industry.April 21, 2017 -
Ribo launched a strategic collaboration with global oligonucleotide pharmaceutical giant, Ionis, USASuzhou Ribo Life Science Co. Ltd., announced today a partnership with the global oligonucleotide pharmaceutical giant Ionis Pharmaceutical Inc. (Nasdaq code: IONS). Furthermore, it signed cooperation and licensing agreements to work together to promote the R&D and commercialization of oligonucleotide pharmaceuticals (or RNA-targeted drugs) in CApril 18, 2017